Eli Lilly and
$1,149.14Change from previous close: −0.69%Absolute change: −$7.94
At a glance
- Revenue growth
- +44.70%
- 2025 vs 2024
- Net income growth
- +94.90%
- 2025 vs 2024
- Net margin
- 31.7%
- 2024: 23.5%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total revenue | 65,179 | 45,043 | 34,124 | 28,541 | — |
| Cost of revenue | 11,052 | 8,418 | 7,082 | 6,630 | — |
| Gross profit | 54,127 | 36,625 | 27,042 | 21,912 | — |
| Selling, general and administrative | 11,094 | 8,594 | 7,404 | 6,440 | — |
| Research and development | 13,337 | 10,991 | 9,313 | 7,191 | — |
| Operating income | 29,696 | 17,040 | 10,325 | 8,280 | — |
| EBIT | 29,696 | 17,040 | 10,325 | 7,138 | — |
| EBITDA | 31,693 | 18,807 | 11,852 | 8,661 | — |
| Interest expense | — | 781 | 486 | 332 | 340 |
| Pre-tax income | 25,731 | 12,680 | 6,554 | 6,806 | — |
| Income tax | 5,091 | 2,090 | 1,314 | 562 | — |
| Net income | 20,640 | 10,590 | 5,240 | 6,245 | — |
| Net income to common shareholders | 20,640 | 10,590 | 5,240 | 6,245 | — |
| Basic EPS | 23.07 | 11.80 | 5.83 | 6.57 | — |
| Diluted EPS | 22.95 | 11.71 | 5.80 | 6.57 | — |
| Average shares (basic) | 895 | 898 | 899 | 950 | — |
| Average shares (diluted) | 899 | 904 | 903 | 950 | — |